The Big Pharma companies have voluntarily agreed to a range of measures to reduce the cost of medicines for American patients while also preserving the biopharmaceutical innovation ecosystem of the U.S.

The Polish company debuts as a European biologics CDMO, offering services from accelerated development through to commercialization using advanced digital tools and mirrored GMP-certified sites.

Innovator companies are increasingly engaging with outsourcing partners in efforts to improve cost and time efficiencies across the complete drug development lifecycle.

Luke Miels, the company’s current Chief Commercial Officer, has been appointed as the new CEO, signaling the company’s next phase after Dame Emma Walmsley’s era of strategic growth and innovation.

While the levies seem steep the impact on industry may be less severe than expected as many companies have a presence or are planning works for manufacturing facilities within the U.S., making them exempt from the tariffs.

Several big players within the bio/pharma industry are pulling back their investments from the United Kingdom amid fears over the security of the country’s life sciences environment.

In this guest blog post, Will Downie and Elliott Berger delve into the key factors that are negatively impacting CDMO revenue performance and highlight the foundational elements that should be adopted to ensure success.

The global healthcare company is expecting that its efforts to streamline operations will allow it to improve the speed of decision making and reinvest savings into pertinent growth opportunities.

Industry leaders delve into the latest biopharma supply chain disruptions and provide insights into approaches that can help to reduce vulnerabilities and ensure greater resilience in the future.

As pharmaceutical packaging evolves to incorporate more patient-centric designs, overcome increasingly complex formulations, and undergo a digital transformation, safety and compliance remain non-negotiables.

D’Herve has succeeded Dr. Singh, bringing a wealth of industry experience to the position, having previously served in senior positions at Evonik.

Recent fatalities in clinical trials for gene therapies have led to greater regulatory scrutiny and concerns over safety, particularly in relation to the use of viral vectors, leading industry to question whether a potential therapeutic reinvention is needed.

In efforts to position itself for long-term growth, Rocket is reducing its company headcount, undergoing a structural reorganization, and prioritizing late-stage AAV cardiovascular programs.

The CDMO model is evolving to incorporate more innovative approaches and specialist capacity as a result of the increasingly complex development pipeline. In this article, The Pharma Navigator editors provide a snapshot of some of the news from CDMOs helping innovators with their formulation requirements.

Increasingly complex and diverse molecules in the development pipeline and greater demand for patient-centricity are leading to a need for developers to employ advanced formulation approaches and strategies.

The oral dosage market is being shaped by a variety of innovations aimed at improving bioavailability, enhancing patient-centricity, and supporting complex molecules with sophisticated formulation solutions.

A new priority review program, unveiled by the FDA with the potential to dramatically reduce the regulatory review process for drug applications, will require increased agility, responsiveness, and readiness from CDMOs with less room for error.

Despite current hurdles facing biopharma and biotech companies, the recent BIO International Convention event saw innovation take center stage and provided a sentiment of optimism for the future, so long as industry does not rest on its laurels.

Drug development companies are struggling to gain financial support because management capabilities are lacking. In this BIO 2025 interview, Ali Pashazadeh from Treehill Partners discusses the investment landscape in more detail.

In this interview, Sarah Griffin from Informa Markets provides a review of CPHI Americas 2025 and teases some potential exciting innovations being planned for the 2026 edition of the conference.